Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.

Most patients with acute myeloid leukemia (AML) achieve complete remission (CR) after induction chemotherapy. Despite ensuing courses of consolidation chemotherapy, a large fraction of patients will experience relapses with poor prospects of long-term survival. Histamine dihydrochloride (HDC) in combination with the T-cell-derived cytokine IL-2 was recently approved within the EU as a remission maintenance immunotherapy in AML. HDC reduces myeloid cell-derived suppression of anti-leukemic lymphocytes, and aims to unravel a therapeutic benefit of IL-2 in AML by improving natural killer and T-cell activation. A randomized Phase III trial with 320 AML patients in CR demonstrated a significant reduction of relapse risk after immunotherapy with HDC plus low-dose IL-2 in the post-consolidation phase. HDC is the first approved therapeutic to target the state of immunosuppression in AML; further development in this area may comprise supplementary or alternative counter-suppressive agents with the aim to improve the efficacy of cancer immunotherapy.
AuthorsAnna Martner, Fredrik B Thorén, Johan Aurelius, Jonas Söderholm, Mats Brune, Kristoffer Hellstrand
JournalExpert review of hematology (Expert Rev Hematol) Vol. 3 Issue 4 Pg. 381-91 (Aug 2010) ISSN: 1747-4094 [Electronic] England
PMID21083028 (Publication Type: Journal Article, Review)
Chemical References
  • Antineoplastic Agents
  • Interleukin-2
  • Histamine
  • Antineoplastic Agents (adverse effects, immunology, therapeutic use)
  • Histamine (adverse effects, immunology, therapeutic use)
  • Humans
  • Immunotherapy
  • Interleukin-2 (adverse effects, immunology, therapeutic use)
  • Leukemia, Myeloid, Acute (drug therapy)
  • Molecular Targeted Therapy
  • Secondary Prevention

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: